Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMAR Amarillo Biosciences		$0.00	$0.05 ▼ $1.97	$25.24M	-0.06	18,253 shs	6,100 shs
BMEA Biomea Fusion	$1.81 -5.2%	$1.92	$1.29 ▼ $13.07	$71.76M	-0.23	1.15 million shs	2.50 million shs
GNLX Genelux	$2.97 +1.7%	$2.66	$1.60 ▼ $5.89	$110.19M	-0.49	191,499 shs	277,488 shs
IOBT IO Biotech	$1.30	$1.15	$0.66 ▼ $1.73	$85.64M	0.36	282,743 shs	57,790 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMAR Amarillo Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
BMEA Biomea Fusion	-5.24%	-23.31%	+24.83%	-36.93%	-62.68%
GNLX Genelux	+1.71%	-2.94%	+19.28%	-24.43%	+25.32%
IOBT IO Biotech	0.00%	-3.70%	+17.12%	+35.43%	+4.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMAR Amarillo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	2.433 of 5 stars	3.6	1.0	0.0	0.0	2.4	2.5	0.6
GNLX Genelux	0.7097 of 5 stars	3.6	0.0	0.0	0.0	0.0	0.0	0.0
IOBT IO Biotech	3.6938 of 5 stars	3.7	5.0	0.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMAR Amarillo Biosciences	0.00	N/A	N/A	N/A
BMEA Biomea Fusion	3.18	Buy	$21.40	1,082.32% Upside
GNLX Genelux	3.20	Buy	$17.75	497.64% Upside
IOBT IO Biotech	3.33	Buy	$9.33	617.95% Upside

Current Analyst Ratings Breakdown

Latest AMAR, GNLX, IOBT, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/14/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	BMEA Biomea Fusion	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $3.00
4/1/2025	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/31/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMAR Amarillo Biosciences	$20K	0.00	N/A	N/A	($0.03) per share	0.00
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
GNLX Genelux	$10K	11,208.78	N/A	N/A	$0.76 per share	3.91
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMAR Amarillo Biosciences	-$1.45M	N/A	0.00	N/A	N/A	-41,453.98%	N/A	-574.29%	N/A
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
GNLX Genelux	-$29.87M	-$0.88	N/A	N/A	N/A	N/A	-93.04%	-74.17%	8/13/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.37	N/A	N/A	N/A	N/A	-162.55%	-125.08%	8/12/2025 (Estimated)

Latest AMAR, GNLX, IOBT, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMAR Amarillo Biosciences	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMAR Amarillo Biosciences	N/A	0.03	0.07
BMEA Biomea Fusion	N/A	2.25	2.25
GNLX Genelux	N/A	4.67	4.67
IOBT IO Biotech	N/A	2.32	2.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMAR Amarillo Biosciences	N/A
BMEA Biomea Fusion	96.72%
GNLX Genelux	37.33%
IOBT IO Biotech	54.76%

Insider Ownership

Company	Insider Ownership
AMAR Amarillo Biosciences	34.35%
BMEA Biomea Fusion	18.42%
GNLX Genelux	9.30%
IOBT IO Biotech	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMAR Amarillo Biosciences	2	42.07 million	N/A	Not Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
GNLX Genelux	10	37.74 million	34.23 million	Not Optionable
IOBT IO Biotech	30	65.88 million	62.72 million	Not Optionable

AMAR, GNLX, IOBT, and BMEA Headlines

Recent News About These Companies

IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Down 35.0% in May

June 17, 2025 | marketbeat.com

IO Biotech (NASDAQ:IOBT) Rating Increased to Sell at Wall Street Zen

June 14, 2025 | americanbankingnews.com

Wall Street Zen Upgrades IO Biotech (NASDAQ:IOBT) to "Sell"

June 14, 2025 | marketbeat.com

Citadel Advisors LLC Purchases Shares of 270,504 IO Biotech, Inc. (NASDAQ:IOBT)

June 7, 2025 | marketbeat.com

IO Biotech Regains Nasdaq Compliance with Stock Price

June 4, 2025 | msn.com

IO Biotech, Inc. (NASDAQ:IOBT) Director Acquires $20,850.00 in Stock

June 3, 2025 | insidertrades.com

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Growth in Short Interest

June 2, 2025 | marketbeat.com

Heidi Hunter Buys 15,000 Shares of IO Biotech, Inc. (NASDAQ:IOBT) Stock

June 2, 2025 | marketbeat.com

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

May 28, 2025 | zacks.com

IO Biotech files for the sale of up to 5.6M shares of common stock for holders

May 23, 2025 | msn.com

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 20, 2025 | globenewswire.com

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

May 15, 2025 | finance.yahoo.com

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025 | globenewswire.com

From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3, 2025 | ajmc.com

IO Biotech unveils promising vaccine preclinical data

April 27, 2025 | investing.com

IO Biotech Presents New Preclinical Data Supporting Dual-Antigen and TGF-β-Directed Vaccines for Enhancing Anti-Tumor Immunity at AACR 2025

April 27, 2025 | nasdaq.com

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 26, 2025 | globenewswire.com

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

April 25, 2025 | globenewswire.com

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

April 12, 2025 | finance.yahoo.com

Piper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)

April 2, 2025 | markets.businessinsider.com

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMAR, GNLX, IOBT, and BMEA Company Descriptions

Amarillo Biosciences OTCMKTS:AMAR

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

Biomea Fusion NASDAQ:BMEA

$1.81 -0.10 (-5.24%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.83%)

As of 06/20/2025 07:49 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Genelux NASDAQ:GNLX

$2.97 +0.05 (+1.71%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.96 -0.02 (-0.51%)

As of 06/20/2025 04:11 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

IO Biotech NASDAQ:IOBT

$1.30 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.30 -0.01 (-0.38%)

As of 06/20/2025 04:04 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time